Last reviewed · How we verify

Zilretta

Sorrento Therapeutics, Inc. · FDA-approved active Small molecule ✓ Verified May 2026

Zilretta is a Small molecule drug developed by Sorrento Therapeutics, Inc.. It is currently FDA-approved. Also known as: triamcinolone acetonide, Extended release triamcinolone acetonide, FX006, Triamcinolone acetonide extended-release.

Zilretta is a brand name for triamcinolone acetonide, a synthetic corticosteroid medication that acts as a glucocorticoid receptor agonist. It is used to treat various joint conditions and inflammation in the body, typically administered by injection into joints or lesions.

At a glance

Generic nameZilretta
Also known astriamcinolone acetonide, Extended release triamcinolone acetonide, FX006, Triamcinolone acetonide extended-release, triamcinolone acetonide, extended release injectable suspension
SponsorSorrento Therapeutics, Inc.
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Zilretta

What is Zilretta?

Zilretta is a Small molecule drug developed by Sorrento Therapeutics, Inc..

Who makes Zilretta?

Zilretta is developed and marketed by Sorrento Therapeutics, Inc. (see full Sorrento Therapeutics, Inc. pipeline at /company/sorrento-therapeutics-inc).

Is Zilretta also known as anything else?

Zilretta is also known as triamcinolone acetonide, Extended release triamcinolone acetonide, FX006, Triamcinolone acetonide extended-release, triamcinolone acetonide, extended release injectable suspension.

What development phase is Zilretta in?

Zilretta is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing